The prognostic value of neutrophil–to-lymphocyte ratio and platelet–to-lymphocyte ratio in the severe COVID-19 cases

Miray Tumer¹, Yavuz Otal¹, Kaan Çelik²
¹Department of Emergency Medicine, Ankara City Hospital, Ankara, Türkiye
²Department of Emergency Medicine, Bolu Abant Izzet Baysal University, School of Medicine, Bolu, Türkiye

ABSTRACT

Aim: COVID-19 is a cause of high-mortality pandemic with the RNA virus in its etiology and has an effect all over the world. In the present study, the relationship between in-hospital prognosis and mortality was investigated by comparing neutrophil-to-lymphocyte ratio (NLR), platelet–to-lymphocyte ratio (PLR) values with C-reactive protein (CRP) and with a detailed analysis of complete blood count and biochemical parameters in mild and severe COVID-19 cases.

Method: A total of 271 patients who were diagnosed with pneumonia because of COVID-19 and 278 healthy control groups were included in the study. In our study, COVID-19 cases were divided into 2 groups as mild and severe, and the data were compared with healthy people without COVID-19. Lung tomography results of the cases that were diagnosed with COVID-19 were examined. Those with positive RT-PCR (Real-Time Polymerized Chain Reaction) test results were recorded from the system. Biochemical tests and complete blood count parameters of the patients, NLR/lymphocyte-to-monocyte ratio (LMR)/PLR N/L, and CRP levels were compared with the control group. The results were evaluated and analyzed in statistical terms.

Results: When all the data were analyzed, NLR/PLR and CRP levels were found to be higher at statistically significant levels in the severe patient group than in the control group, and LMR was lower (p<0.01). In ROC analysis, NLR/PLR and CRP had a high AUC (area under the curve) (0.844/0.719/0.501) and LMR had a low AUC (0.225).

Conclusion: NLR and PLR might be useful in demonstrating the prognosis in severe COVID-19 cases.

Key words: SARS-CoV-2, neutrophil-to-lymphocyte ratio, platelet–to-lymphocyte ratio, C-reactive protein, lymphocyte-to-monocyte ratio.

Introduction
The SARS-CoV-2 disease pandemic started in China/Wuhan at the end of 2019 (COVID-19). Many people have died since then [1]. Because of its high contagiousness, people have had to be hospitalized and live under long-term quarantine. It still maintains its disease-causing effects by undergoing various mutations. Also, it was shown in many studies that COVID-19 and its variants cause high morbidity and mortality [2-4].

Some parameters in serum in COVID-19 cases were investigated as a prognostic indicator before. white blood cell (WBC), neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP) levels, which are acute phase reactants,
guide in showing the severity of the disease [5-7].
In the present study, the relationship between in-hospital prognosis and mortality was investigated by comparing NLR, platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) values with CRP and with a detailed analysis of complete blood count and biochemical parameters in mild and severe COVID-19 cases.

**Materials and methods**

After the approval of the Ethics Committee of Ankara City Hospital with the 2021/2043 the blood samples taken from 271 patients and 278 healthy volunteers from the diagnosed COVID-19 cases were examined in the laboratory, and the data were analyzed.

In our study, COVID-19 cases were divided into 2 groups as mild and severe, and the data were compared with healthy people without COVID-19. Computed lung tomography results of the cases that were diagnosed with COVID-19 were examined. Those with positive RT-PCR (Real-Time Polymerized Chain Reaction) results were also included. Biochemical values, complete blood count parameters, WBC, NLR, PLR, LMR, and CRP values of all subjects included in the study were entered into a separate statistical program.

Admission criteria for severe cases:
1- Those whose blood oxygen saturation does not exceed 90 despite oxygen therapy
2- Those who need respiratory support
3- Those with hypotension
4- Those with tachypnea

Admission criteria for mild cases:
1- Those with lung involvement and oxygen saturation above 90
2- Those who do not need respiratory support
3- Normotensives
4- Those without tachypnea

Those who were under the age of 18, trauma patients, and pregnant women were excluded from the study.

**Statistical analysis**

The Statistical Package for Social Sciences for Windows, Version 22 (IBM, Armonk, NY, USA) was used for statistical analyses. The Kolmogorov-Smirnov Test was used for the normality of the variables. Non-normal distribution data were represented by the median (interquartile range). The Mann-Whitney U Test was used to compare the mean values between the groups. The categorical variables were summarized as numbers and percentages in each category. The Chi-Square and Fisher’s Exact Test were used for categorical variables. Optimal threshold values of continuous age, CRP, NLR, PLR, and LMR were calculated by applying the Receiver Operating Curve (ROC) analysis. The Binary Logistic Regression Analysis was performed to determine the effect of age, gender, and all other important factors. The Hosmer-Lemeshow Goodness-Of-Fit statistics were used to evaluate the model fit and \( p < 0.05 \) was considered statistically significant.

**Results**

No significant differences were detected between the control and patient group in terms of age, neutrophils, NLR, LMR, and PLR and although WBC, lymphocyte, monocyte, hemoglobin, and platelet were lower in the patient group than in the control group, CRP was found to be higher (Table 1).

Table 1 presents routine blood parameters in mild and severe groups. Routine blood examinations were performed at admission to 128 mild and 143 severe patients in total. WBC, neutrophil, NLR, and PLR were significantly higher in the severe group than in the mild case group. Lymphocytes and LMR were lower in the severe group than in the non-severe group (Table 2). No significant
Table 1. Blood routine parameters characteristics of control and COVID-19 patients group.

| Parameters          | Control (n = 278) | COVID-19 patients (n = 271) | p Value |
|---------------------|-------------------|-----------------------------|---------|
| Age (years)         | 58 (44-72), 21-93 | 60.5, (42-74), 20-91        | 0.245   |
| Gender, male/female | 145/133           | 160/111                     | 0.048   |
| Leucocytes, (×10⁹ /L) | 7.49 (6.75-10.53) | 6.69 (5.44-9.01)           | <0.001  |
| Neutrophils, (×10⁹ /L) | 4.75 (3.24-7.66)  | 4.39 (3.08-7.01)           | 0.262   |
| Lymphocytes, (×10⁹ /L) | 2.05 (1.26-2.53)  | 1.56 (0.94-2.25)           | 0.003   |
| Monocytes, (×10⁹ /L)  | 0.47 (0.36-0.69)  | 0.42 (0.31-0.59)           | 0.002   |
| Hemoglobin (g/L)    | 13.6 (12.6-14.5)  | 13.3 (11.2-14.7)           | 0.028   |
| Platelet, (×10⁹ /L) | 247.5 (198.75-303.5) | 188.8 (139.2-236.8)       | <0.001  |
| NLR                 | 2.46 (1.5-5.44)   | 2.67 (1.58-6.14)           | 0.290   |
| LMR                 | 4.65 (2.19-5.97)  | 3.77 (2.03-5.99)           | 0.409   |
| PLR                 | 131.38 (100.3-184.16) | 116.04 (69.72-193.1)     | 0.083   |
| hsCRP, g/L          | 0.004 (0.001-0.005) | 0.08 (0.01-0.21)         | <0.001  |

Values: median (IQR); NLR: neutrophil-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio; PLR: platelet-to-lymphocyte ratio; hs-CRP: high-sensitivity C-reactive protein.

Table 2. Blood routine parameters of severe and non-severe group of COVID-19.

| Parameters          | Non-severe (n = 128) | Severe (n = 143) | p Value |
|---------------------|----------------------|------------------|---------|
| Age (years)         | 50 (33-67), 18-93    | 60.5, (42-74), 20-91 | 0.004   |
| Gender, male/female | 80/48                | 80/63            | 0.038   |
| Leucocytes, (×10⁹ /L) | 6.32 (5.30-7.80)     | 8.21 (5.65-11.31) | <0.001  |
| Neutrophils, (×10⁹ /L) | 3.6 (2.87-4.77)     | 6.19 (3.85-9.65) | <0.001  |
| Lymphocytes, (×10⁹ /L) | 2.03 (1.53-2.49)    | 0.99 (0.62-1.51) | <0.001  |
| Monocytes, (×10⁹ /L)  | 0.42 (0.30-0.55)     | 0.45 (0.31-0.64) | 0.276   |
| Hemoglobin (g/L)    | 14 (12.8-15)         | 11.7 (9.8-14.1)  | <0.001  |
| Platelet, (×10⁹ /L) | 188.8 (140-236.8)    | 184 (129-239.2)  | 0.946   |
| NLR                 | 1.77 (1.32-2.7)      | 5.81 (3.24-12.64) | <0.001  |
| LMR                 | 5.3 (3.32-7.23)      | 2.55 (1.53-4.03)  | <0.001  |
| PLR                 | 88.9 (59.5-136)      | 165 (98.5-289.4)  | <0.001  |
| hsCRP, g/L          | 0.082 (0.03-0.26)    | 0.09 (0.03-0.18)  | 0.960   |
| ESR, mm/hour        | 16 (10-36)           | 44 (30-79)       | <0.001  |
| Ferritin, µg/L      | 55 (30-166)          | 198 (97.75-421)  | <0.001  |
| Ferritin/ESR        | 3.86 (1.5-8.66)      | 4.5 (2.2-12.2)   | 0.044   |

Values: Median (IQR); NLR: Neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; PLR: Platelet-to-lymphocyte ratio; hs-CRP: High-sensitivity C-reactive protein; ESR: Erythrocyte sedimentation rate.

Differences were detected between the severe and mild case groups in terms of CRP, monocyte count, and platelet counts. When compared with the mild case group, severe patients were significantly older (median age, 60.5 years [IQR, 42.0-74.0] and 50.0 years [33.0-67.0]; p = 0.004).

**ROC curve results**

Figure 1 shows that the severe group was
Figure 1. ROC curve was applied to evaluate patients with severe and non-severe COVID-19. NLR: Neutrophils-to-lymphocytes ratio; MLR: Monocyte-to-lymphocytes ratio; PLR: Platelet-to-lymphocytes ratio.

Table 3. AUC values of NLR, PLR, LMR and CRP.

| Parameters | AUC  | Std. Error | Asymptotic Sig. | Asymptotic 95% Confidence Interval |
|------------|------|------------|-----------------|-----------------------------------|
|            |      |            |                 | Lower Bound                       | Upper Bound                       |
| Age        | 0.603| 0.035      | 0.004           | 0.535                             | 0.671                             |
| CRP        | 0.501| 0.035      | 0.972           | 0.432                             | 0.571                             |
| NLR        | 0.844| 0.024      | <0.001          | 0.796                             | 0.891                             |
| LMR        | 0.225| 0.028      | <0.001          | 0.169                             | 0.280                             |
| PLR        | 0.719| 0.032      | <0.001          | 0.657                             | 0.781                             |

AUC: area under the curve; CRP: C-reactive protein; NLR: Neutrophils-to-lymphocytes ratio; MLR: Monocyte-to-lymphocytes ratio; PLR: Platelet-to-lymphocytes ratio. Asymptotic significance less than 0.05 were considered significant.

Table 4. The odds ratio results.

| Parameters | Unadjusted ORs | p value | Adjusted ORs | p value |
|------------|----------------|---------|--------------|---------|
|            | OR (95%CI)     |         | OR* (95%CI)  |         |
| WBC        | 0.972 (0.854-1.107) | 0.668   | 0.983 (0.861-1.123) | 0.804   |
| CRP        | 0.613 (0.152-2.474) | 0.492   | 0.510 (0.121-2.153) | 0.359   |
| NLR        | 1.481 (1.220-1.798) | <0.001  | 1.438 (1.184-1.748) | <0.001  |
| LMR        | 0.889 (0.774-1.021) | 0.095   | 0.883 (0.770-1.012) | 0.073   |
| PLR        | 1.001 (0.997-1.005) | 0.609   | 1.001 (0.997-1.005) | 0.541   |

WBC: White blood cell; CRP: C-reactive protein; NLR: Neutrophils-to-lymphocytes ratio; MLR: Monocyte-to-lymphocytes ratio; PLR: Platelet-to-lymphocytes ratio.
progression. The possible effects of age and gender were excluded and the adjusted OR was obtained after adjusting for gender and age, as CBC parameters are affected by age and gender. The results showed that NLR was significantly correlated with the risk of COVID-19 (adjusted OR: 1438, \( p < 0.001 \)) (Table 4). However, the risks of WBC, CRP, PLR, and LMR were not clear.

**Discussion**

Some changes in the blood values help clinicians in the diagnosis of patients with COVID-19. Lymphopenia, leukocytosis, neutrophilia, and an increase in N/L Ratios are frequently observed changes. Lymphopenia is a common finding and is considered to occur because of an inadequate immune response to the virus. Studies are arguing that hypercytokinemia might be the cause of lymphopenia. In this case, the clinical course of the disease becomes severe, and acute respiratory failure called ARDS, which can result in mortality, might occur [8].

CRP is among the inflammatory markers and is an acute-phase protein synthesized by hepatocytes. In the present study, it was found that CRP levels increased in COVID-19 patients in response to proinflammatory cytokines, which were reported to be increased in most of the previous studies [9, 10]. CRP, a biomarker indicating systemic inflammation, was found to be high in our study.

Many studies have shown in recent years that some ratios of complete blood count parameters are significant in showing the severity of the disease. Some of these rates are NLR, LMR, and PLR, and these rates were used in the diagnosis and prognosis of many inflammatory conditions. Yang et al. reported that age, WBC count, NLR, LMR, PLR, and CRP were significantly elevated in severe patients when compared to other patients, and the lymphocyte count was significantly lower [11]. In the present study, contrary to the study of Yang et al., LMR was low in severe cases, and WBC, NLR, PLR, and CRP were high. In the study of Lissoni et al. and Zhang et al., the LMR value was found to be similar to our results and lower in cases with a severe course [12, 13].

High NLR is an increased risk factor for in-hospital mortality. Although neutrophils increase in COVID-19 cases, the decrease in lymphocytes ends with an increase in NLR. There are publications associated with the severity of the disease with high NLR (14, 15). In the present study, although NLR and PLR increased, LMR decreased.

Qu et al. He argued that high PLR levels in the blood parameters of 30 patients with a diagnosis of COVID-19 were associated with the prognosis of the disease [16]. Although the rate of PLR did not differ significantly between severe and mild patients, they found that it was significantly higher when high platelet count was achieved. In this study, the PLR value was found to be significantly higher in severe cases, suggesting that it can give an idea to clinicians in showing the severity of the disease. There are some publications in which the optimum cut-off value for some serum biochemical parameters was determined by using the severe disease ROC curve as a prognosis indicator in COVID-19 [17]. The %LUC levels can be used as independent prognostic indicators. In the present study, NLR had the highest AUC in the PLR analysis. According to ROC analysis, NLR and PLR AUC values, which are considered acute phase reactants in COVID-19 infection, are significant in showing disease prognosis. The highest specificity and sensitivity were in NLR, PLR. According to these results, NLR and PLR can be used to predict the severity of the disease.

The study had some limitations. Serial reviews could not be performed on the patients because
of financial and logistical constraints. The sample size was small and more extensive studies are needed. In conclusion, our study revealed that NLR is an independent risk factor in determining the severity of COVID-19 disease. In addition, patients with high platelets and longer mean hospital stays may be associated with cytokine storm. We believe that further research is needed to compare and confirm our results, as comprehensive analysis of clinical and admission laboratory parameters to identify patients with a severe prognosis is important not only for the follow-up of patients, but also for determining the pathophysiology of the disease.

**Funding:** The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Conflict of Interest:** The authors declare that they have no conflict of interest.

**Ethical Statement:** Ankara City Hospital local ethics committee and institutional review board approved the study protocol (Approval no: 2021/2043).

**Open Access Statement**

Experimental Biomedical Research is an open access journal and all content is freely available without charge to the user or his/her institution. This journal is licensed under a Creative Commons Attribution 4.0 International License. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author.

**Copyright (c) 2021:** Author (s).

**References**

[1] Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization, 2020.

[2] Tao RJ, Luo XL, Xu W, et al. Viral infection in community acquired pneumonia patients with fever: a prospective observational study. J Thorac Dis. 2018;10(7): 4387–95.

[3] Henry BM, Aggarwal G, Wong J, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med. 2020;38(9):1722-1726.

[4] Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382 (18):1708–20.

[5] Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. J Med Virol. 2020;92(10):1733-34.

[6] Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6-e12.

[7] Smilowitz NR, Kuniochff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021;42(23):2270-79.

[8] Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int. 2020;44(9):1792-97.

[9] Seyit M, Avci E, Nar R, et al. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. Am J Emerg Med. 2021;40:110-14.

[10] Deng Y, Liu W, Liu K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a
[11] Yang AP, Liu JP, Tao WQ, et al. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.

[12] Lissoni P, Rovelli F, Colciago M, et al. Evidence of Abnormally Low Lymphocyte-To-Monocyte Ratio In Covid-19-Induced Severe Acute Respiratory Syndrome. J Immuno Allerg. 2020;1(2):1-6.

[13] Zhang H, Cao X, Kong M, et al. Clinical and hematological characteristics of 88 patients with COVID-19. Int J Lab Hematol. 2020;42(6):780-787.

[14] Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6-e12.

[15] Shahid MF, Malik A, Siddiqi FA, et al. Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count as Early Diagnostic Tools for Corona Virus Disease 2019. Cureus. 2022;14(3):e22863.

[16] Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020;92(9):1533-1541.

[17] Bastug A, Bodur H, Erdogan S, et al. Clinical and laboratory features of COVID-19: Predictors of severe prognosis. Int Immunopharmacol. 2020;88:106950.